Shares of Sanofi-Aventis (NYSE:SNY) traded at a new 52-week high today of $48.48. Approximately 268,000 shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares.

Potential upside of 9.1% exists for Sanofi-Aventis, based on a current level of $48.47 and analysts' average consensus price target of $52.87. The stock should find initial support at its 50-day moving average (MA) of $45.31 and further support at its 200-day MA of $40.58.

Over the past year, Sanofi-Aventis has traded in a range of $33.03 to $48.48 and is now at $48.47, 47% above that low. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.4% while the 200-day MA has risen 0.3%.

Sanofi-Aventis is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

SmarTrend recommended that subscribers consider buying shares of Sanofi-Aventis on November 23rd, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $44.72. Since that recommendation, shares of Sanofi-Aventis have risen 7.5%. We continue to monitor SNY for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.